BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

...Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) FMX103 Moderate to severe papulopustular rosacea Top-line Ph III data Mid-2018 Futura Medical plc...
BioCentury | Jan 13, 2017
Company News

Futura, Stada Arzneimittel deal

...to inquiries. Futura Medical plc (LSE:FUM), Guildford, U.K. Stada Arzneimittel AG (Xetra:SAZ), Bad Vilbel, Germany Business: Neurology Nora Weintraub TPR100 Futura Medical plc Stada...
BioCentury | Oct 31, 2016
Financial News

Futura Medical completes placing

Futura Medical plc (LSE:FUM), Guildford, U.K. Business: Drug delivery, Neurology, Genitourinary Date completed: 2016-10-27 Type: Placing Raised: L12 million ($14.7 million) Shares: 21.1 million Price: 57p Shares after offering: 120.1 million Placement agent: N+1 Singer...
BioCentury | Oct 10, 2016
Clinical News

Glyceryl trinitrate: Phase II data

...The trial evaluated >=4 topical applications of MED2002 immediately before sexual intercourse over 4 weeks. Futura Medical plc...
BioCentury | May 16, 2016
Clinical News

Glyceryl trinitrate: Completed Phase II enrollment

...trial evaluating >=4 topical applications of 300 mg MED2002 prior to intercourse over 4 weeks. Futura Medical plc...
BioCentury | Apr 4, 2016
Finance

2Q milestones

...Group (Euronext:IPN) Cometriq cabozantinib Second-line treatment for metastatic renal cell carcinoma (RCC) PDUFA date 6/22/16 Futura Medical plc...
BioCentury | Jan 11, 2016
Finance

Sowing season

...Zilretta triamcinolone acetonide Moderate to severe OA pain Ph III data; submit NDA 1Q16; 2H16 Futura Medical plc...
BioCentury | Jul 13, 2015
Clinical News

Eroxon: Phase III started

...to evaluate 4 doses of 300 mg topical MED2002 over 4 weeks in 192 patients. Futura Medical plc...
BioCentury | Mar 17, 2014
Financial News

Futura Medical proposes placing

Futura Medical plc (LSE:FUM), Guildford, U.K. Business: Genitourinary, Neurology, Drug delivery Date announced: 3/7/14 Type: Placing To be raised: £12 million ($20 million) Shares: 21.1 million Price: 57p Shares outstanding prior: 77.9 million Advisor: N+1...
BioCentury | Jul 15, 2013
Company News

Futura Medical, GlaxoSmithKline deal

...their well-established APIs and that no further clinical data is required to obtain regulatory approval. Futura Medical plc...
Items per page:
1 - 10 of 15
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

...Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) FMX103 Moderate to severe papulopustular rosacea Top-line Ph III data Mid-2018 Futura Medical plc...
BioCentury | Jan 13, 2017
Company News

Futura, Stada Arzneimittel deal

...to inquiries. Futura Medical plc (LSE:FUM), Guildford, U.K. Stada Arzneimittel AG (Xetra:SAZ), Bad Vilbel, Germany Business: Neurology Nora Weintraub TPR100 Futura Medical plc Stada...
BioCentury | Oct 31, 2016
Financial News

Futura Medical completes placing

Futura Medical plc (LSE:FUM), Guildford, U.K. Business: Drug delivery, Neurology, Genitourinary Date completed: 2016-10-27 Type: Placing Raised: L12 million ($14.7 million) Shares: 21.1 million Price: 57p Shares after offering: 120.1 million Placement agent: N+1 Singer...
BioCentury | Oct 10, 2016
Clinical News

Glyceryl trinitrate: Phase II data

...The trial evaluated >=4 topical applications of MED2002 immediately before sexual intercourse over 4 weeks. Futura Medical plc...
BioCentury | May 16, 2016
Clinical News

Glyceryl trinitrate: Completed Phase II enrollment

...trial evaluating >=4 topical applications of 300 mg MED2002 prior to intercourse over 4 weeks. Futura Medical plc...
BioCentury | Apr 4, 2016
Finance

2Q milestones

...Group (Euronext:IPN) Cometriq cabozantinib Second-line treatment for metastatic renal cell carcinoma (RCC) PDUFA date 6/22/16 Futura Medical plc...
BioCentury | Jan 11, 2016
Finance

Sowing season

...Zilretta triamcinolone acetonide Moderate to severe OA pain Ph III data; submit NDA 1Q16; 2H16 Futura Medical plc...
BioCentury | Jul 13, 2015
Clinical News

Eroxon: Phase III started

...to evaluate 4 doses of 300 mg topical MED2002 over 4 weeks in 192 patients. Futura Medical plc...
BioCentury | Mar 17, 2014
Financial News

Futura Medical proposes placing

Futura Medical plc (LSE:FUM), Guildford, U.K. Business: Genitourinary, Neurology, Drug delivery Date announced: 3/7/14 Type: Placing To be raised: £12 million ($20 million) Shares: 21.1 million Price: 57p Shares outstanding prior: 77.9 million Advisor: N+1...
BioCentury | Jul 15, 2013
Company News

Futura Medical, GlaxoSmithKline deal

...their well-established APIs and that no further clinical data is required to obtain regulatory approval. Futura Medical plc...
Items per page:
1 - 10 of 15